Cargando…
A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis
BACKGROUND: Epidemiological evidence suggests that moderately elevated levels of circulating insulin-like growth factor-I (IGF-I) are associated with increased risk of breast cancer in women. How circulating IGF-I may promote breast cancer incidence is unknown, however, increased IGF-I signaling is...
Autores principales: | Dearth, Robert K, Kuiatse, Isere, Wang, Yu-Fen, Liao, Lan, Hilsenbeck, Susan G, Brown, Powel H, Xu, Jianming, Lee, Adrian V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189189/ https://www.ncbi.nlm.nih.gov/pubmed/21867536 http://dx.doi.org/10.1186/1471-2407-11-377 |
Ejemplares similares
-
ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis
por: Campbell, Craig I, et al.
Publicado: (2010) -
Krt6a-Positive Mammary Epithelial Progenitors Are Not at Increased Vulnerability to Tumorigenesis Initiated by ErbB2
por: Holloway, Kimberly R., et al.
Publicado: (2015) -
Mammary Cells with Active Wnt Signaling Resist ErbB2-Induced Tumorigenesis
por: Bu, Wen, et al.
Publicado: (2013) -
The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis
por: Wellberg, Elizabeth A., et al.
Publicado: (2016) -
Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells - interplay of ErbB and IGF1 signalling through IGFBP3 regulation
por: Worthington, Jenny, et al.
Publicado: (2010)